human prostate cancer tissue arrays (SuperBioChips)
Structured Review

Human Prostate Cancer Tissue Arrays, supplied by SuperBioChips, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+prostate+tissue+array/human+prostate+tissue+array/pmc07281005-173-0-8
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Crosstalk between Prostate Cancer Cells and Tumor-Associated Fibroblasts Enhances the Malignancy by Inhibiting the Tumor Suppressor PLZF"
Article Title: Crosstalk between Prostate Cancer Cells and Tumor-Associated Fibroblasts Enhances the Malignancy by Inhibiting the Tumor Suppressor PLZF
Journal: Cancers
doi: 10.3390/cancers12051083
Figure Legend Snippet: Promyelocytic leukemia zinc finger (PLZF) inhibits the activation of STAT3, which has an inverse correlation with PLZF. ( A ) IHC of PLZF, pY-STAT3 in tissue arrays of surrounding normal prostate tissues, and human prostate cancer specimens correlates with Gleason scores (GS). Quantification of PLZF-positive expression according to the GS in normal tissues adjacent to the benign tumors ( n = 9) and malignant tumors ( n = 40) (right). ( B ) Associations between expression of PLZF and pY-STAT3. Scatter plots showing the linear correlation determined by Pearson correlation coefficient calculation of those genes that were statistically significant. Pearson correlation coefficient r and p -values are given in each scatter plot. ( C ) PSA levels were measured according to the PLZF and pY-STAT3 protein levels, n = 40. ( D ) Kaplan–Meier recurrence-free survival analysis of prostate cancer patients according to PLZF (* p = 0.0344) and pY-STAT3 (* p < 0.0001) expression. ( E ) Quantification of PLZF mRNA expression according to the GS and metastasis in prostate cancer patients’ samples, *** p < 0.0001. ( F ) PLZF, pY-STAT3, STAT3, and GAPDH protein expression by Western blotting in the prostate cancer cell lines DU145 and LNCaP. GAPDH was used as a loading control. ( G ) Western blotting was performed in PLZF, CA-STAT3 plasmid, and siRNA-transfected cells. The uncropped blots and molecular weight markers of are shown in
Techniques Used: Activation Assay, Expressing, Western Blot, Control, Plasmid Preparation, Transfection, Molecular Weight
Figure Legend Snippet: Tyrosine phosphatase SHP-1 is a direct target of PLZF and inhibits the tyrosine phosphorylation of JAKs–STAT3 signaling. ( A ) Western blotting was performed in PLZF-transfected DU145 cells. ( B ) Protein expression levels of the tyrosine phosphatase-related markers STAT3, JAK2, and TYK2 were detected by Western blotting. ( C ) mRNA expression levels of tyrosine phosphatases were examined by RT-PCR and qRT-PCR in DU145 and LNCaP cells. ( D ) Western blotting of SHP-1, STAT3, JAK2, and TYK2 in cells that were co-transfected with PLZF and si-SHP-1. ( E ) SHP-1 reporter assay in DU145 and LNCaP cells transfected with PLZF plasmid and siRNA. ( F ) IHC of SHP-1 in tissue arrays of surrounding normal prostate tissues and human prostate cancer specimens correlates with GS. Quantification of SHP-1-positive expression according to the GS scores in benign ( n = 9) and malignant tumors ( n = 40) (right). ( G ) Associations between SHP-1 and PLZF. Scatter plots showing the linear correlation determined by Pearson correlation coefficient calculation of those genes that were statistically significant. Pearson correlation coefficient r and p-values are given in each scatter plot. ( H ) PSA levels were measured according to the SHP-1 protein levels, n = 40. ( I ) Kaplan–Meier recurrence-free survival analysis of prostate cancer patients according to SHP-1 (* p < 0.0001) expression. In C, E, and F data are presented as the mean ± SD; * p < 0.05, *** p < 0.001. The uncropped blots and molecular weight markers of are shown in
Techniques Used: Phospho-proteomics, Western Blot, Transfection, Expressing, Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Reporter Assay, Plasmid Preparation, Molecular Weight
Figure Legend Snippet: Loss of CCL3 inhibits the fibroblast-induced prostate cancer cells migration and invasion. ( A ) Each CM was applied to the cytokine arrays (top). The cytokines in boxes are more enriched in co-cultured CM than in fibroblast CM. Mean intensities of cytokines are plotted (bottom). ( B ) PNT2, LNCaP, and DU145 cells were co-cultured with fibroblast in a cell culture chamber for 24 h. Cells in a lower chamber were lysed for qRT-PCR. ( C ) LNCaP cells were treated with the indicated conditioned media with the addition of an anti-CCL3 antibody or anti-uPAR antibody and then subjected to Western blotting. ( D ) Concentrations of CCL3 in the indicated conditioned media were analyzed using an ELISA kit. Summarized results from three independent experiments were quantified as the mean ± SD. ( E ) Cells, which had been transfected with the luciferase plasmid, were pre-treated with recombinant protein CCL3 for 4 h, incubated under FCM or Co-CM for 24 h. ( F ) LNCaP cells, which had been pre-treated with anti-CCL3 antibody for 4 h, were incubated in the indicated CMs for 24 h. The relative cell numbers are shown (right). In B, D, E, and F, representative images from three independent experiments were quantified as the mean ± SD; * p < 0.05, ** p < 0.01, *** p < 0.001. The uncropped blots and molecular weight markers of are shown in
Techniques Used: Migration, Cell Culture, Quantitative RT-PCR, Western Blot, Enzyme-linked Immunosorbent Assay, Transfection, Luciferase, Plasmid Preparation, Recombinant, Incubation, Molecular Weight
Related Articles
other:Article Title: Crosstalk between Prostate Cancer Cells and Tumor-Associated Fibroblasts Enhances the Malignancy by Inhibiting the Tumor Suppressor PLZF Article Snippet: Human prostate cancer tissue arrays were purchase from Article Title: Elevated NF-κB/SHh/GLI1 Signature Denotes a Worse Prognosis and Represent a Novel Potential Therapeutic Target in Advanced Prostate Cancer Article Snippet: Article Title: Targeting PKLR/MYCN/ROMO1 signaling suppresses neuroendocrine differentiation of castration-resistant prostate cancer Article Snippet: Immunohistochemical (IHC) staining The tissue microarray (TMA) set, which included 40 cases of prostatic carcinoma and 10 cases of benign prostatic tissue, was purchased from Immunohistochemistry:Article Title: Loss of EGR3 is an independent risk factor for metastatic progression in prostate cancer. Article Snippet: Identification of pro-metastatic genomic alterations is urgently needed to help understand and prevent the fatal course of prostate cancer.. Here, we found that the transcription factor EGR3, located at chromosome 8p21.3, is a critical metastasis suppressor.. Aberrant deletion of EGR3 was found in up to 59.76% (deep deletions, 16.87%; shallow deletions, 42.89%) of prostate cancer patients. Article Title: Peptide-conjugated nanoparticles for targeting, imaging, and treatment of prostate cancer Article Snippet: .. Binding Analysis of Phage Clones to Clinical Tumor Surgical Specimens by Immunohistochemistry A Tissue:Article Title: Mucosa-Associated Lymphoid Tissue 1 Is an Oncogene Inducing Cell Proliferation, Invasion, and Tumor Growth via the Upregulation of NF-κB Activity in Human Prostate Carcinoma Cells Article Snippet: .. The Binding Assay:Article Title: Peptide-conjugated nanoparticles for targeting, imaging, and treatment of prostate cancer Article Snippet: .. Binding Analysis of Phage Clones to Clinical Tumor Surgical Specimens by Immunohistochemistry A Clone Assay:Article Title: Peptide-conjugated nanoparticles for targeting, imaging, and treatment of prostate cancer Article Snippet: .. Binding Analysis of Phage Clones to Clinical Tumor Surgical Specimens by Immunohistochemistry A Microarray:Article Title: Peptide-conjugated nanoparticles for targeting, imaging, and treatment of prostate cancer Article Snippet: .. Binding Analysis of Phage Clones to Clinical Tumor Surgical Specimens by Immunohistochemistry A |


